Troriluzole is an experimental medication that has been investigated as a potential treatment for MachadoâÂÂJoseph disease (MJD), obsessiveâÂÂcompulsive disorder (OCD), and glioblastoma. It is a prodrug formulation of the medication riluzole.
While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.
In 2024, researchers published a study in the Journal of Neurochemistry that reported troriluzole could reverse some early Alzheimer's disease brain changes in mice, reduce harmful glutamate levels, and improve memory and learning abilities.